Ocata Therapeutics, Inc. (now owned by Acucela) announced on March 31, 2015 that the company has completed dosing of its Phase 1/2 studies for dry age-related macular degeneration (AMD) and Stargardt’s Macular Degeneration (SMD). A total of 38 patients have been safely dosed. The 200,000 cell cohort, the highest level planned, was successfully completed, paving [Read More]
News
All About Eyeglasses
For something so important, most people know very little about their eyeglasses. What do those abbreviations and numbers on the prescription mean? Why do my friend and I have the same prescription numbers, when my vision is so much worse? What does 20/20 mean? If my best vision without glasses is 20/200, am I legally [Read More]
Encapsulated Cell Technology Could Replace Injections in Wet AMD Patients
Neurotech Pharmaceuticals, Inc. announced on March 30, 2015 that the FDA has approved a Phase 2 clinical study of NT-503 Encapsulated Cell Therapy (ECT) for the treatment of wet age-related macular degeneration (AMD). ECT is an intravitreal implant that is genetically engineered to produce the biologic anti-VEGF drug NT-503 for at least 2 years. ECT, therefore, acts like [Read More]
What They Really Mean . . .
Sometimes, it’s wise to read news items in reverse. by Dan Roberts The latest magnifying technology, a switchable telescopic contact lens, has been receiving wide media attention this past week. If you read the news from the top down, and you anxiously call your eye care specialist before reading all the way to the bottom, [Read More]
Notal Vision Device Shows 94% Success at Early Detection of Age-Related Macular Degeneration
A National Eye Institute study has reported an impressive success rate at early detection of wet (neovascular) age-related macular degeneration (AMD). The study compared two groups of dry AMD patients and compared the proportion within each group for patients presenting with 20/40 acuity or better when their wet AMD was detected. An experimental group used [Read More]